Stephens & Co. Initiates Coverage On Centessa Pharmaceuticals with Overweight Rating, Announces Price Target of $35
Author: Benzinga Newsdesk | October 28, 2025 05:10am
Stephens & Co. analyst Sudan Loganathan initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Overweight rating and announces Price Target of $35.